Zelluna is currently building a comprehensive pipeline of immunotherapeutic drug candidates based on the company's TCR portfolio.

We are developing candidates both for use in adoptive cell therapy (ACT) and as soluble TCRs in combination with a range of effector functions.

Our TCRs target TGFβRII, KRAS and hTERT which are widely expressed in a range of cancer types currently lacking efficient treatment. Our lead candidate TCR is expected to enter initial clinical testing in 2018 and we have multiple candidates in early and late stage pre-clinical development.